BEAM Alliance News

EU-JAMRAI: BEAM Alliance becomes a new stakeholder
BEAM Alliance, BEAM Alliance
— April 2018 — 35 views

Antibiotic resistance: Nosopharm and the University of Illinois at Chicago describe mechanism of action of new class of antibiotics in Molecular Cell
NOSOPHARM
— April 2018 — 9 views

Combioxin Announces Completion of CAL02 FIM Trial in Patients with Severe Pneumococcal Pneumonia
Combioxin SA
— March 2018 — 55 views

Polyphor announces enrollment of first patient in Phase III clinical trial for murepavadin – a pathogen-specific antibiotic being developed for the treatment of nosocomial pneumonia
Polyphor Ltd
— March 2018 — 15 views

Allecra Therapeutics Announces Positive Top-Line Results from Phase 2 CACTUS Study of its Lead Candidate, AAI101, in Combination with Cefepime to treat complicated Urinary Tract Infections (cUTI)
ALLECRA THERAPEUTICS
— March 2018 — 16 views

First publication from Antabio’s novel metallo-β-lactamase (MBL) inhibitor program
ANTABIO S.A.S
— March 2018 — 11 views

The BEAM Alliance is speaking at the 10th Community of Users Meeting - Health session "Preparedness and response to Infectious Disease Threats" in Brussels
BEAM Alliance, BEAM Alliance
— March 2018 — 52 views

Basilea reports clinical phase 3 study start with antibiotic ceftobiprole in skin infections under BARDA contract
Basilea Pharmaceutica International Ltd.
— February 2018 — 34 views

Debiopharm continues the fight against antibiotic resistance with investment in ABAC Therapeutics Inc.
Debiopharm International
— February 2018 — 24 views

Dossier Antibiothérapie - Thérapie antibactérienne
BEAM Alliance, BEAM Alliance
— February 2018 — 41 views

Dossier Antibiothérapie - Menace bactérienne
BEAM Alliance, BEAM Alliance
— February 2018 — 38 views

Dossier Antibiothérapie - Incitations à l’investissement
BEAM Alliance, BEAM Alliance
— February 2018 — 27 views

Polyphor: Global No. 2 in the 2018 Biopharmaceuticals Antimicrobial Resistance Benchmark published by the Access to Medicine Foundation
Polyphor Ltd
— January 2018 — 22 views

Results of Clinical Trial for DAV132 Published in JID
DA VOLTERRA
— January 2018 — 257 views

The first major scientific article on the antimicrobial peptide SAAP-148 appeared today in Science Translational Medicine.

Madam Therapeutics BV
— January 2018 — 154 views

Madam Therapeutics received an award in the NECTAR program
Madam Therapeutics BV
— December 2017 — 159 views

BioVersys AG successfully closes Series A2 financing round
BioVersys AG
— November 2017 — 145 views

Da Volterra is a partner in the new COMBACTE-CDI consortium
DA VOLTERRA
— November 2017 — 93 views

November 16th, 2017: New BEAM Alliance Position Paper calls out worldwide stakeholders to support SME-driven innovation and revive the product pipeline fighting antimicrobial resistance
BEAM Alliance, BEAM Alliance
— November 2017 — 1080 views

AiCuris Announces that its Licensee MSD Received Positive CHMP Opinion for PREVYMIS™ (Letermovir) Recommending Approval in Europe
AiCuris Anti-infective Cures GmbH
— November 2017 — 156 views

Improving the fate of severely infected patients: the promise of anti-toxin treatments and superiority trials
Combioxin SA
— November 2017 — 121 views

Mutabilis joins the European ENABLE consortium to fight antibiotic resistance
Mutabilis SAS
— October 2017 — 155 views

ANTABIO raises € 7.3M Series A Financing to Develop Novel Treatments against Drug-Resistant Gram-negative infections
ANTABIO S.A.S
— October 2017 — 180 views

Eligo Bioscience Secures $20 Million Series A from Khosla Ventures and Seventure to Bring Precision Medicine to the Microbiome
Eligo Bioscience
— September 2017 — 120 views

Stay updated :

Participate on our social stream.

Archives

Tags